- Category: Pipeline
Pipeline
Bausch + Lomb dry eye combo drop advances to phase 3 evaluation
Formulation includes active ingredients of XIIDRA and MIEBO; positive data also reported on a first-in-class drop for targeting ocular pain signaling.
Pipeline
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy
EYC-0305 is under evaluation as a potential long-acting treatment designed for 6-month or longer dosing intervals via IVT injection.
Pipeline
Kodiak enrolls first patients in phase 3 DME study for bispecific therapy
KSI-501 advances to two registrational phase 3 trials, with topline data for wet AMD expected in Q3 2026.
Pipeline
Sumitomo Pharma America doses first patient in RP cell therapy trial
Phase 1/2a trial evaluating DSP-3077 as a regenerative cell therapy is estimated to complete in October 2028.
Pipeline
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.
Pipeline
Oculis buys out privosegtor’s global rights from Accure
Updated deal includes total purchase of development and commercial rights as company advances its phase 3 PIONEER program for ON.
Pipeline
FDA accepts Belite's tinlarebant NDA for Stargardt
Federal agency also grants priority review for the once-daily oral therapeutic, establishing a PDUFA target action date for Feb. 12, 2027.
Pipeline
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy
Topline 6-month efficacy data is expected by the end of 2027, with the goal of supporting a BLA.
Pipeline
4DMT reports new phase 2b gene therapy data for wet AMD
New 2-year data demonstrates an overall 78% treatment reduction in patients treated with 4D-150 compared to bimonthly 2 mg aflibercept.
Pipeline
Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study
US 510(k) study to evaluate glaucoma drainage device for IOP reduction among OAG patients who failed previous medical and surgical treatment.
Pipeline
Claris Bio raises $118M to advance first-ever LSCD therapy
Financing to support ongoing and planned clinical trials evaluating CSB-001 (oremepermin alfa ophthalmic solution) as a topical ocular biologic eye drop.
Pipeline
Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt
Findings released at ASRS highlight an 80% reduction in key protein implicated in Stargardt disease after 2 years.
Pipeline
FDA forms advisory committee to review Sydnexis's low-dose atropine
Federal agency to discuss phase 3 clinical data supporting SYD-101 for the treatment of pediatric progressive myopia following NDA rejection.
Pipeline
Kowa submits NDA for NCX 470, a IOP-lowering glaucoma drop
Pending FDA review, Nicox’s NO-donating bimatoprost formulation could receive approval and commercially launch by the end of 2027.
Pipeline
Dompé begins enrollment for phase 3 trial on NAION intranasal therapy
Intranasal cenegermin takes another step towards being the first FDA-approved treatment for NAION.
Pipeline
Lexitas, Ocusun dose first patient in pilot study for age-related cataract eye drop
Derived from a naturally-occurring steroid molecule, ZOC2017217 is a potential alternative treatment that could reshape the landscape of cataract care.
Pipeline
Provectus and VisiRose patent light-free eye drop for drug-resistant BK
Intellectual property covers topical RBS ophthalmic solution against resistant Gram-positive bacteria without the need for light activation.
Pipeline
RegenxBio doses first patient in phase 2b/3 trial for DR
One-time gene therapy continues to move down the pipeline, with presentations on efficacy and safety data expected at ASRS.
Pipeline
OKYO's urcosimod gets FDA nod, moves to global phase 3 trial for NCP
Positive Type D meeting feedback supports topical therapeutic’s continued path toward becoming the first approved treatment for neuropathic corneal pain.
Pipeline